Connect with us


Cannabotech opens ‘first of its kind’ flagship store in Westfield Shopping Centre

The new London location is just one of many planned for across Europe showcasing their unique formulas for medicinal mushrooms and CBD



Cannabotech: The front of the new store in Westfield

The new Cannabotech store offers cutting edge technology allowing customers to scan their health while shopping.

The store offers new technology that allows customers to have their health scanned in-store. The My Being™ technology reads the blood vessels in the skin before giving a reading on a person’s stress levels, blood pressure, heart rate and breathing.

This can help the Cannabotech team to make tailored recommendations for each person’s requirements. Customers can also log their health journey to see the changes they have made over time.

The brand is also one of the first companies to combine the benefits of medicinal mushrooms with CBD.

Speaking with Cannabis Health News, Elchanan Shaked CEO of Cannabotech explained why the UK was the perfect location for the store.

“Our idea is to combine different strategies of Cannabotech including a physical store, online activity and we might open clinics in the UK. We believe this way, we will build a lot of trust and give a lot of education from our strong scientific team. The UK is a leader in the CBD market and an early adopter of the latest developments in the industry.”

Westfield is just the beginning as the company plan to open other branches next year in different locations. They are also interested in expanding to other parts of Europe such as Germany, Austria and Switzerland. They plan to launch in California next year.

Cannabotech’s M²CBD formula

The unique M²CBD formula of Cannabotech products combines traditional mushrooms for the different health concerns they have identified. The store features stand for each health concern such as ageing or stress. Mushrooms include reishi, lion’s mane and cordyceps among others. The product range includes skincare, oils and food supplements.

READ MORE  Could cannabis promote weight loss?

Medical mushrooms are a growing industry. Industry research and investment website, Market Watch estimated that medical mushrooms were worth US$3557 in 2020. This looks set to increase by 7 per cent by 2027.

Dr Basem Fares, R&D director of Cannabotech said: “We did a lot of research into the delivery systems and solubility of CBD isolate, which we use in the product along with various compounds of medical mushrooms. We focus on the dosage that is needed to get the bio effect we are looking for in each product. We have a patent about the delivery system itself and a second one about the mixtures and different doses of CBD used in each product.”

Cannabotech: Two of the presentation tables displaying Cannabotech products in store

When it comes to CBD and mushrooms, how aware are consumers of the health benefits they could offer?

Dr Yuval Heled, Integrative and Exercise Physiologist, part of the scientific board at Cannabotech explained: “Our job is to educate people. This is definitely part of the company, for us as preventive health care scientists, to educate people on how to achieve better health. We give them another tool in their toolbox for healthy living.”

Cannabotech technology

The store is equipped with the latest technology to help customers identify any health concerns. It can also offer an interactive educational experience.

“We have a lot of technical elements that start with face-scanning to show your existing wellbeing status. We can measure you by a selfie, from your smartphone so we can see your blood pressure, stress and five other physiological matters. We also have a play table with the latest technology where you can answer any question you may have.”

READ MORE  Endometriosis, CBD and self-care: "It doesn’t get the recognition that it should"

The play table is an interactive space in the centre of the store which allows customers to find the answer to any questions they may have about mushrooms or CBD. Placing one of the tubes onto the table, allows customers to select individual mushrooms or see how the endocannabinoid system works with CBD.

Cannabotech: The play table instore allowing customers to learn about mushrooms

Cannabotech visit

Cannabis Health News editor, Caroline Barry decided to visit Cannabotech to learn about the benefits of mushrooms and have her health scanned.

“I try to stay as healthy as I possibly can but I often don’t have time to get my health checked as much as I would like to. I like that Cannabotech offers me the chance to pop in while shopping to check how I’m doing. While it felt like a bit like taking a strange selfie while standing in the store, the scan was extremely quick offering me results in under ten minutes.”

“The scan was quick to report my heart rate and stress levels, which were elevated due to getting slightly lost in Westfield shopping centre. I was happy to see that most of my vitals were in the average range. If the scan identifies something as ‘poor’ then it can be broken down to show you why. It was a relief to see my overall physical vitals described as ‘good.’

“The staff were incredibly friendly and knowledgeable about mushrooms, while I grow my own lion’s mane and oyster varieties at home, it was fun to play with the tech table to learn more. It’s a great entry point for anyone interested in the benefits of mushrooms and CBD who hasn’t used either before.”

READ MORE  Only 1 in 4 CBD edibles contain the labeled amount of CBD

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Study: States with full legal access show fewer registered medical cannabis patients

“If true, this could have implications for public health and policy,” say researchers.



Study shows U.S states where cannabis is legal for recreational purposes have experienced a decrease in patients registering for medical cannabis programmes.

The study on different US states, published in the International Drug Journal, revealed that numbers of registered and active medical cannabis consumers increased while it was not legal for recreational use.

Researchers in Arizona took data from the medical cannabis registry from two dozen states between 2013 and 2020.  These are mandatory registries that record the number of medical cannabis patients. They analysed the data to see if there were any changes around the times that recreational legalisation was introduced.

There are currently 19 states in the US that have legalised recreational cannabis including New Jersey, Vermont, Arizona and New York. However, more states have medical cannabis programs although some are still not operational. Some states such as Colorado have had recreational access since 2012, the year before the study was started.

Medical cannabis patients

The results confirmed that medical cannabis cardholders increased during times when recreational use was not legal. It then subsequently decreased when it became legal.

It also revealed an increase of 380 patients per 100,000 people per year when just medical cannabis was legal. This corresponded to a decrease of 100 patients per 100,000 after recreational cannabis was allowed. The researchers noted that active registered active male patients decreased faster than women. In states where only medical cannabis was legal, the older age groups (35 or older), increased faster.

They also found that in three states with medical-only use, the results showed significant increases in enrollment from 2016 to 2020 across white, African-American and Hispanic patients.

READ MORE  Fibromyalgia relief: New review suggests cannabis may help symptoms

The researchers wrote: “There is speculation that enrollment in U.S. state medical cannabis programs differs depending on whether adult recreational cannabis use is legal. If true, this could have implications for public health and policy.”

“Findings suggest that recreational cannabis legalisation is associated with decreasing enrollment in medical cannabis programs, particularly for males.”

Medical Cannabis: A banner advert for subscribing to cannabis health

Continue Reading


Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access

The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.



Zerenia clinic: doctor holding medical cannabis
The clinic will initially prescribe for chronic pain and mental health conditions.

Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.

Zerenia Clinics, which launched in the UK in recent weeks, has joined a growing number of clinics on Project Twenty21 (T21), as it aims to make medical cannabis more affordable for patients. 

The clinic also offers competitive costs, with consultation fees at £80. 

The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.

Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for. 

Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK. 

“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.

“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”

Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis. 

“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.

“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”

She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”

Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic. 

Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here

READ MORE  Only 1 in 4 CBD edibles contain the labeled amount of CBD
Continue Reading


CiiTECH to launch medicinal cannabis range Provacan THC in Israel

Israeli patients will have access to the first Provacan THC oil in January 2022, followed by Brazilian and British patients.



CiiTECH: The logo for Ciitech

CiiTECH and Cannassure have announced a major deal to develop and market Provacan THC products for medical cannabis use in Israel.

It marks CiiTECH’s long-awaited move into medicinal cannabis.

In addition to offering established consumer CBD brands, CiiTECH’s flagship brand Provacan is considered one of the most respected in the UK.

Clifton Flack, CEO and founder of CiiTECH, intends to bring Provacan’s reputation for quality and consistency to the troubled Israeli medical cannabis market.

“CiiTECH is unique in its approach to the CBD wellness and medicinal cannabis markets. We built an international reputation as a market-leading CBD company by producing pharmacy trusted CBD oil tinctures and selling them as food supplements before making our move into THC. Our intention is to bring these International standards to the Israeli market,” says Flack.

“As a UK company with strong roots in Israel, CiiTECH is well-positioned to make its THC debut and there is no better place to do so than in Israel, the epicentre of global cannabis research.”

Cannassure is known for producing high-grade medical cannabis in Israel with an advanced indoor-aeroponic growing system and state-of-the-art extraction.”

CiiTECH collaboration

The collaboration with CiiTECH, a leading company in the field of cannabis research and marketing and owner of the leading brand Provacan, is an important step in the field of cannabis oils for us, an area that enjoys significant growth among patients who do not want to consume inflorescence cannabis. We are confident that this collaboration will bring value for us, for CiiTECH and for cannabis patients in Israel, and we believe that it will help us conquer a more significant share of the cannabis oil market in Israel,” said Ran Amir, Cannassure CEO.

READ MORE  Fibromyalgia relief: New review suggests cannabis may help symptoms

As part of its business strategy, CiiTECH seeks and collaborates with best-of-breed cannabis providers up and down the supply chain in multiple geographies. With this agreement, CiiTECH continues to demonstrate its effective business strategy, commitment to quality assurance, and speed of entry into the market that the industry has grown to expect from CiiTECH.

With the help of Cannassure, CiiTECH will help reform, standardise, educate and establish quality, consistency, and reliability in the Israeli medical cannabis market. In order to achieve this goal, CiiTECH is developing a hybrid solution in which a superior quality product is offered to patients and a unique professional enrichment program is offered to help doctors and pharmacists support patients on a deeper level.

CiiTECH education

Around 80 per cent of Israel’s 100,000 licensed medical cannabis users smoke, rather than using tinctures. The biggest complaint in those groups is the lack of quality and consistency. It is CiiTECH’s mission to show these users how much better tinctures are than smoking. Provacan ambassadors and users will benefit from comprehensive education courses provided by CiiTECH as part of this re-education so they will feel more confident and better supported while using CiiTECH products.

“As cannabis market experts and our involvement in the cannabis ecosystem in Israel, we understand the nature of the demand and the gaps in the Israeli market. Our new THC tincture will revolutionise the lives of many patients who are currently suffering from inconsistencies in the medical cannabis supply chain, and it will be made to the same strict UK and European guidelines as our current products,” concluded Flack.

READ MORE  Presidential glow could boost US cannabis interest

Israeli patients will have access to the first Provacan THC oil in January 2022, followed soon by Brazilian and British patients.

Ciitech: A banner advertising collaborative content

Continue Reading